SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based ...
Bionano Genomics, Inc. today announced the Stratys ™ system for high throughput optical genome mapping (OGM) and VIA ™ software for visualization, interpretation and reporting of genome analysis for ...
Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The ...
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key ...
Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The ...
Join us for an installment of our Bionano In Motion webinar series as our speakers delve into immunotherapies and the emerging role of optical genome mapping (OGM) in assessing genome integrity as ...
New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high ...
A study in The Journal of Molecular Diagnostics assessing the efficacy of optical genome mapping (OGM) in a cohort of patients with acute leukemia has demonstrated that OGM provided reliable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results